

N4 Pharma plc
("N4 Pharma" or the "Company")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.

Resolution	For	For%	Against	Against%	Total	Withheld votes*
Ordinary Resolution 1 To receive the annual report and audited accounts for the year ended 31 December 2023	20,612,844	99.93%	13,980	0.07%	20,626,824	296,841
Ordinary Resolution 2 To re-elect Nigel Theobald as a Director of the Company	20,605,744	99.32%	141,080	0.68%	20,746,824	176,841
Ordinary Resolution 3 To re-elect David Templeton as a Director of the Company	20,605,744	99.32%	141,080	0.68%	20,746,824	176,841
Ordinary Resolution 4 To re-appoint Saffery Champness LLP as the Company's auditor and to authorise the Directors to determine their remuneration	20,605,644	99.32%	140,980	0.68%	20,746,624	177,041
Ordinary Resolution 5 To authorise the Directors to allot shares	20,559,085	99.10%	187,539	0.90%	20,746,624	177,041
Special Resolution 6 To disapply pre-emption rights	20,506,310	99.00%	207,439	1.00%	20,713,749	209,916

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

For more information please contact:

N4 Pharma plc

Nigel Theobald, CEO
Luke Cairns, Executive Director

investors.n4pharma.com

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia Brzozowska
(Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate
Broking)

Tel: +44(0)20 3470 0470

InvestorHub

Engage with us directly at N4 Pharma Investor Hub

Sign up at investors.n4pharma.com

<https://investors.n4pharma.com/link/Ky0AZe>

Turner Pope Investments (TPI) Limited

Joint Broker
Andy Thacker
James Pope

Tel: +44(0)20 3657 0050

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGBBGDUIBDDGSX